For decades, general health and science information has served as the foundation for public understanding of medical risks and patient safety. This legacy framework emphasizes broad awareness of treatment benefits and potential adverse effects, often communicated through standardized channels to diverse audiences. In the context of mass production environments—where consistency and efficiency are paramount—such general health guidance may not fully address the specific vulnerabilities of workers handling pharmaceutical agents. As the focus narrows from population-level health communication to occupational exposure, a critical shift occurs. The transition from general health context to Tysabri exposure and Progressive Multifocal Leukoencephalopathy (PML) risk requires acknowledging that manufacturing personnel face distinct, repeated contact with biologic therapies. Unlike patients who receive intermittent doses under medical supervision, workers in production settings may encounter these substances through routine handling, maintenance, or accidental exposure. This occupational dimension introduces questions about cumulative risk and regulatory timelines, particularly regarding legal recourse. In Washington, the statute of limitations for claims related to Tysabri-associated PML becomes a pivotal consideration for those whose exposure occurred in the course of employment. Thus, the legacy of general health information now pivots to a focused inquiry: how do mass production realities shape the legal and medical landscape for workers potentially affected by this therapy?
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Washington who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations—including the statute of limitations—is critical. PML is an opportunistic viral infection of the brain caused by the JC virus, typically occurring only in immunocompromised patients, and it usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri increases the risk of PML, and three key risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment, and physicians must weigh expected benefit against PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, vision changes, cognitive decline, and coordination problems. Diagnosis typically involves MRI imaging and detection of JC virus DNA in cerebrospinal fluid. Because PML can be rapidly debilitating, early recognition is essential. The prescribing information mandates that healthcare professionals monitor patients for any new signs or symptoms suggestive of PML and withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier. This reduces inflammatory activity in the central nervous system, which is beneficial for multiple sclerosis but also impairs normal immune surveillance. The resulting immunosuppression within the brain allows latent JC virus to reactivate and cause PML. The risk is highest in patients with anti-JCV antibodies, as these antibodies indicate prior exposure to the virus. The duration of therapy is another critical factor, with risk increasing significantly after two years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Prior use of immunosuppressants further compounds this risk by weakening the immune system before Tysabri is even started.
The prescribing information for Tysabri includes a boxed warning that explicitly states the increased risk of PML and the factors that elevate that risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to be enrolled, read a Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Pharmacies and infusion centers must also be specially certified (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions about the adequacy of risk communication have arisen in litigation, particularly regarding whether patients and physicians fully understood the magnitude of PML risk and the need for vigilant monitoring.
For patients in Washington who have developed PML after Tysabri use, legal claims may be pursued against the manufacturer, Biogen, for failure to adequately warn about PML risks. The statute of limitations for product liability and personal injury claims in Washington is generally three years from the date the injury was discovered or reasonably should have been discovered. This timeline is critical because PML symptoms may develop gradually, and the exact date of harm can be difficult to pinpoint. The timeline between Tysabri exposure and documented PML harm can vary from months to several years, with risk increasing after two years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who received Tysabri and later developed PML should consult with an attorney promptly to determine whether their claim falls within the applicable statute of limitations. Settlement-related considerations for affected patients include the severity of disability, medical expenses, lost income, and pain and suffering. Because PML often leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), settlements may be substantial but depend on individual circumstances. Patients should also be aware that Tysabri is indicated only as monotherapy and should not be used with immunosuppressants or TNF-alpha inhibitors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), as combination therapy may further elevate PML risk.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Washington, the statute of limitations for product liability and personal injury claims is generally three years from the date the injury was discovered or reasonably should have been discovered. Because PML symptoms may develop gradually, it is crucial to consult an attorney promptly to determine if your claim falls within this timeframe.
Three key risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.